VistaGen Therapeutics - VTGN Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VistaGen Therapeutics in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VTGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VTGN, but not buy additional shares or sell existing shares.
View VTGN analyst ratings or view top-rated stocks.

4 equities research analysts have issued 1 year price objectives for VistaGen Therapeutics' stock. Their VTGN share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 5,455.6% from the stock's current price.
View analysts price targets for VTGN or view top-rated stocks among Wall Street analysts.

VistaGen Therapeutics' stock was trading at $1.95 at the beginning of 2022. Since then, VTGN stock has decreased by 91.7% and is now trading at $0.1620.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our VTGN earnings forecast.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Thursday, August, 11th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.01. The company earned $0.31 million during the quarter, compared to analyst estimates of $0.34 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 88.13% and a negative net margin of 5,614.37%.

Based on aggregate information from My MarketBeat watchlists, some companies that other VistaGen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE), Lithium Americas (LAC), ImmunoGen (IMGN), Yamana Gold (AUY) and CRISPR Therapeutics (CRSP).

VistaGen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

VistaGen Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Commodore Capital LP (6.31%), Acuta Capital Partners LLC (5.50%), Franklin Resources Inc. (4.57%), State Street Corp (1.89%), MAI Capital Management (1.29%) and Epiq Partners LLC (0.63%). Insiders that own company stock include H Ralph Snodgrass, Jerrold Duane Dotson, Jerry B Gin, Reid G Adler, Shawn Singh and Venrock Healthcare Capital Par.
View institutional ownership trends.

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VTGN stock can currently be purchased for approximately $0.16.

VistaGen Therapeutics (NASDAQ:VTGN) has a market capitalization of $33.51 million and generates $1.11 million in revenue each year. The company earns $-47,760,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

VistaGen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.vistagen.com. The company can be reached via phone at (650) 577-3600, via email at ir@vistagen.com, or via fax at 888-482-2602.